The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Non-Small Cell Lung Cancer (NSCLC) Market From 2026 To 2030?
The non-small cell lung cancer (nsclc) market has seen substantial expansion in its size over recent years. Forecasts indicate it will expand from $42.2 billion in 2025 to reach $46.65 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. This historical growth is attributable to factors such as the high incidence of smoking, exposure to environmental air pollution, diagnoses occurring at advanced stages, a scarcity of specific targeted treatment alternatives, and a dependence on traditional chemotherapy methods.
The market size for non-small cell lung cancer (nsclc) is projected to experience substantial growth in the upcoming years. It is expected to expand to $70.81 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period can be attributed to the increasing uptake of targeted therapies and immunotherapy, rising investment in lung cancer diagnostics, the progression of personalized medicine, the expansion of oncology centers and specialty clinics, and the development of AI-based predictive models and imaging solutions. Prominent trends within the forecast period include the increasing adoption of targeted therapy and immunotherapy, a greater utilization of advanced radiotherapy techniques, the growing application of laser therapy and photodynamic therapy, the broadening deployment of early diagnosis and screening programs, and the advancing integration of AI-powered imaging and predictive oncology.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
What Drivers Are Influencing The Non-Small Cell Lung Cancer (NSCLC) Market?
The non-small cell lung cancer (NSCLC) market is anticipated to expand due to the rising incidence of tobacco use. Tobacco consumption involves individuals utilizing tobacco products, commonly through smoking, chewing, or snuffing, thereby introducing nicotine and various chemicals into their systems. Multiple carcinogens present in tobacco smoke can harm the DNA (deoxyribonucleic acid) within lung cells, resulting in mutations and the unchecked proliferation of cancerous cells, such as non-small-cell lung cancer (NSCLC). As an illustration, data from the 2024 National Youth Tobacco Survey, released in October 2024 by the US Food and Drug Administration (USFDA), a US federal agency, showed that 1.1% of all students (approximately 2.25 million) currently used tobacco products. This included 10.1% of high school students (about 1.58 million) and 5.4% of middle school students (around 640,000) consuming tobacco. Furthermore, 2.8% of students (about 760,000) reported current use of any combustible tobacco product, and 3.0% (approximately 840,000) reported using multiple tobacco products. Consequently, the rising prevalence of tobacco consumption is fueling the expansion of the non-small cell lung cancer (NSCLC) market.
Which Segments Are Included In The Analysis Of The Non-Small Cell Lung Cancer (NSCLC) Market?
The non-small cell lung cancer (nsclc) market covered in this report is segmented –
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laser Therapy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Which Trends Are Impacting The Growth Of The Non-Small Cell Lung Cancer (NSCLC) Market?
Leading companies in the non-small cell lung cancer market are prioritizing the development of targeted therapies, such as those receiving FDA accelerated approval for drugs addressing specific genetic mutations, to improve treatment options for patients. FDA accelerated approval is a regulatory path where the U.S. Food and Drug Administration (FDA) grants earlier approval for therapies that precisely target a molecular or genetic anomaly in a disease, based on surrogate or intermediate clinical endpoints deemed reasonably likely to predict clinical benefit. For instance, in July 2025, Dizal (Jiangsu) Pharmaceutical Co., Ltd., a research-focused biotechnology company based in China, introduced sunvozertinib (Zegfrovy) for adult patients suffering from locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who had progressed after platinum-based chemotherapy. Zegfrovy is administered orally, 200 mg once daily with food, continuing until disease progression or unacceptable toxicity occurs. The therapy demonstrated a confirmed overall response rate of 46% and a duration of response of 11.1 months during the WU-KONG1B trial. The FDA approval also mandated the Oncomine Dx Express Test as a companion diagnostic for identifying eligible patients. Sunvozertinib includes warnings regarding interstitial lung disease, gastrointestinal and dermatologic reactions, ocular toxicity, and embryo-fetal toxicity, reflecting its overall safety profile.
Which Key Industry Participants Are Active In The Non-Small Cell Lung Cancer (NSCLC) Market?
Major companies operating in the non-small cell lung cancer (nsclc) market are Pfizer Inc., F. Hoffmann‑La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Clovis Oncology, Revolution Medicines, Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company Limited, BeiGene Ltd., DualityBio, Gilead Sciences Inc., Mirati Therapeutics Inc., Arcus Biosciences Inc., NeoImmuneTech
Read the full non-small cell lung cancer (nsclc) market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Small Cell Lung Cancer (NSCLC) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
Browse Through More Reports Similar to the Global Non-Small Cell Lung Cancer (NSCLC) Market 2026, By The Business Research Company
Cervical Spondylosis Treatment Global Market Report
Osteoarthritis Global Market Report
https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report
Ankylosing Spondylitis Global Market Report
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model